Pediatric Genetic Testing: Suspected Immunodeficiency Roadmap

The clinical presentation may point toward an inborn error of immunity, but the diagnostic pathway usually moves in stages: first establishing whether the immune system is functioning abnormally, then identifying which immune compartment is affected, and finally looking for a molecular explanation.

That sequence matters because pediatric genetic testing for immunodeficiency is not a substitute for initial immunological assessment. Genetic sequencing is most useful when it is interpreted alongside the child’s infection history, growth and quality of life, vaccine record, family history, blood counts, immunoglobulin levels, and cellular immune studies. The timeline is therefore shaped not only by laboratory processing, but also by how clearly the clinical picture defines the next question.

From clinical suspicion to molecular confirmation

The first step is not usually genetic. We begin with a careful clinical assessment and baseline laboratory testing, because the immune phenotype often determines which genetic test will be most informative.

A clinician may consider an inborn error of immunity when infections are unusually severe, persistent, difficult to treat, caused by opportunistic organisms, or associated with complications outside the expected pattern. Recurrent sinopulmonary infections can suggest an antibody deficiency, while invasive bacterial or fungal infections, persistent viral disease, chronic diarrhea, failure to thrive, or profound lymphopenia may raise concern for a combined or cellular immune disorder. Autoimmunity, unexplained inflammation, unusual malignancy, and severe reactions to live vaccines can also form part of the clinical presentation.

The initial laboratory pathway commonly includes:

• A complete blood count with differential, including attention to the absolute lymphocyte and neutrophil counts.
• Quantitative IgG, IgA, and IgM measurements, interpreted in relation to the child’s age rather than against adult reference ranges.
• Lymphocyte immunophenotyping by flow cytometry, which can define the proportions of T cells, B cells, and natural killer cells.
• Additional functional or antibody-response testing when the clinical picture indicates a possible defect in humoral immunity.
• Review of previous laboratory results, because a single abnormal value may reflect acute infection, treatment, age-related variation, or a transient change rather than a stable immune disorder.

Flow cytometry is particularly useful because it moves the assessment from a general concern about immunity toward a more specific immune phenotype. The presence or absence of major lymphocyte populations does not, by itself, identify the responsible gene, but it can substantially narrow the management pathway. A child with markedly reduced T cells requires a different level of urgency from a child whose lymphocyte numbers are preserved but whose antibody production is impaired.

Genetic testing then becomes part of a wider diagnostic process. Depending on the suspected disorder, the laboratory may use a targeted gene panel, whole-exome sequencing, or another next-generation sequencing strategy. These approaches examine many genes at once and are now central to the evaluation of genetically heterogeneous immune disorders. Routine Sanger sequencing is not generally the primary screening approach when the phenotype could arise from a broad range of genes.

Genetic sequencing can explain an immune phenotype, but it cannot replace the immune phenotype that gives the result clinical meaning.

Why the order of testing affects the timeline

The genetic sequencing immunodeficiency process is often described as if it were a single laboratory event: blood is collected, DNA is analyzed, and a diagnosis appears. In practice, the timeline includes several decision points.

Before a sample is sent, the clinical team may need to confirm that the child’s findings are persistent, repeat an abnormal blood count, clarify whether immunoglobulin levels are age appropriate, or complete flow cytometry. A genetics service may then decide whether a focused panel is suitable or whether the phenotype is broad enough to justify exome-based testing.

After sequencing, the result still requires interpretation. A laboratory may identify a pathogenic or likely pathogenic variant, a variant whose significance is uncertain, or no currently explanatory variant. The clinical team must then ask whether the finding fits the child’s immune phenotype, inheritance pattern, laboratory profile, and family history. In some cases, parental testing is needed to determine whether a variant is inherited, newly occurring, or present in a configuration that changes its significance.

This is why the pediatric immunology genetic test results timeline should be understood as a pathway rather than a promised date. A targeted commercial gene panel may have a standard turnaround of approximately four weeks, but the broader process can take longer when samples require additional studies, parental testing, variant review, or a multidisciplinary discussion.

The role of newborn screening in early detection of SCID

Newborn screening changes the diagnostic situation because it can identify a serious immune abnormality before the child develops a major infection.

Screening for severe combined immunodeficiency, or SCID, commonly uses a dried blood spot to measure T-cell receptor excision circles, known as TREC. These small DNA circles are produced during T-cell development and serve as an indirect marker of newly generated T cells. A markedly abnormal TREC result can indicate that the infant has very low T-cell production and requires urgent follow-up.

Some screening programs also evaluate kappa-deleting recombination excision circles, or KREC, to provide information about B-cell production. KREC analysis may help identify disorders involving impaired B-cell development, including conditions such as X-linked agammaglobulinemia. The precise screening algorithm varies by program, so an abnormal result should be interpreted according to the laboratory’s established follow-up protocol.

A positive or abnormal newborn screen is not the same as a final diagnosis. Prematurity, medical illness, specimen-related issues, and conditions outside classic SCID can affect screening results. The next steps may include repeat or confirmatory testing, lymphocyte enumeration by flow cytometry, functional immune studies, and urgent consultation with pediatric immunology.

The major clinical advantage is timing. If a newborn with severe T-cell lymphopenia is identified before exposure to a serious infection, the care team can take protective measures while the immune evaluation proceeds. In a child with suspected or confirmed T-cell or combined immunodeficiency, live-attenuated vaccines such as rotavirus, measles-mumps-rubella, varicella, and the live intranasal influenza vaccine should be avoided until the child has received clear immunological guidance. The decision is not a routine vaccine scheduling issue; it is part of immediate risk management.

What TREC and KREC screening can and cannot tell us

TREC screening is designed to detect a major reduction in newly produced T cells. It does not detect every form of immune deficiency. In particular, it should not be presented as a universal test for all late-onset, partial, or “leaky” forms of SCID, nor does a normal screen exclude every future immune problem.

Similarly, KREC testing provides information about B-cell production but does not replace quantitative immunoglobulin testing, vaccine-response assessment, or genetic analysis. Newborn screening is an early detection tool, not a complete map of the immune system.

For families, this distinction prevents two opposite misunderstandings. An abnormal screen is not proof that a particular gene or treatment will be needed, while a normal screen does not eliminate the possibility of an immune disorder that emerges later in childhood.

Targeted panels versus whole-exome sequencing

The choice between a targeted panel and whole-exome sequencing depends on the clinical question, the breadth of the suspected phenotype, the child’s urgency, and the laboratory’s ability to interpret the findings.

A targeted panel examines a selected group of genes associated with immune disorders. It can be a practical option when the clinical presentation and immune phenotype strongly suggest a defined group of conditions. It may also reduce the number of unrelated findings that require interpretation. Across reported pediatric inborn error of immunity cohorts, targeted next-generation sequencing panels have produced diagnostic rates generally ranging from 15% to 46%, with results influenced by patient selection, panel composition, and disease heterogeneity.

Whole-exome sequencing examines the protein-coding regions of many genes simultaneously. It is particularly useful when the presentation is atypical, when several immune pathways could be involved, or when earlier testing has not produced an explanation. The overall diagnostic yield for WES in suspected inborn errors of immunity is approximately 40% in the available research summary, although that figure should not be treated as a guarantee for an individual child.

The percentages describe diagnostic yield across studied groups, not the probability that any one child will receive a definitive answer. A negative genetic test can mean that the responsible gene is not included, that the relevant variant type was not detected, that the variant remains difficult to interpret, or that the child’s condition is not caused by a single-gene immune disorder.

Why panel selection deserves clinical discussion

A panel is not simply “small exome sequencing.” Its value depends on the genes included, the quality of coverage, the laboratory’s variant interpretation, and whether the panel is updated as new immune-disease genes are recognized. More than 485 to 550 monogenic genes have been identified in the broader field of inborn errors of immunity, depending on classification and the date of review. No fixed panel should be assumed to contain every clinically relevant gene.

The immune phenotype should guide the choice. For example, a child with profound lymphopenia and abnormal T-cell results may need an urgent combined-immunodeficiency evaluation, while a child with recurrent bacterial respiratory infections and low immunoglobulins may enter a different testing pathway. In both cases, genetic analysis should remain connected to functional immunology rather than being ordered as an isolated search through a large database.

The Trio-WES advantage and genetic mimickers

When whole-exome sequencing is selected, testing the child and both biological parents can provide information that is not available from the child’s sample alone. This approach is called parent-proband Trio-WES.

In the cited comparison, Trio-WES produced a diagnostic yield of approximately 51.43%, compared with 33.78% for singleton testing. The advantage comes from inheritance analysis. A variant that appears new in the child may be more suspicious in one disease context, while a change inherited from both parents may support a recessive condition. Parental results can also help clarify whether two variants are located on different copies of a gene, a detail that may be necessary before a recessive diagnosis is considered convincing.

Trio testing does not make interpretation automatic. Some disorders have variable expression, incomplete penetrance, mosaicism, or inheritance patterns that are difficult to resolve through standard exome analysis. The absence of a molecular diagnosis also does not invalidate the clinical evidence of immune dysfunction.

The importance of non-IEI mimickers

One of the most useful findings from broad genetic testing is that the explanation may not lie in a recognized inborn error of immunity gene. In atypical pediatric presentations, comprehensive sequencing can identify pathogenic variants in non-IEI genes in up to 15.2% of cases. These are sometimes described as genetic mimickers because they can produce infections, inflammation, cytopenias, poor growth, or immune dysregulation that resemble a primary immune disorder.

This possibility has practical consequences. A variant outside a traditional immunodeficiency classification may redirect the child toward metabolic, hematologic, rheumatologic, neurologic, or syndromic management. It may change surveillance, medication selection, reproductive counseling, and the assessment of other family members.

The result should therefore be reviewed in a clinical genetics and immunology setting whenever possible. A laboratory report is a starting point for interpretation, not the endpoint of the management pathway. We need to know whether the variant explains the child’s actual immune abnormalities, whether it predicts a recognizable disease course, and whether it changes immediate safety decisions.

Reading the result without losing the clinical picture

Genetic reports commonly use categories such as pathogenic, likely pathogenic, variant of uncertain significance, or no significant finding. These categories are not interchangeable.

A pathogenic or likely pathogenic variant may provide a molecular diagnosis, but the team still confirms that the gene-disease association fits the child’s clinical presentation. A variant of uncertain significance should not be used alone to label a child with a lifelong immune disorder or to make irreversible treatment decisions. Its interpretation may change as population data, functional research, family studies, and disease knowledge develop.

A report with no definitive finding also has several possible meanings:

1. The child may have an immune disorder caused by a gene not yet associated with the phenotype.

2. The relevant change may be in a region or variant type that the selected test does not assess well.

3. The clinical abnormality may be acquired, temporary, multifactorial, or caused by a non-IEI gene.

4. The available evidence may not yet be strong enough to classify an identified variant.

5. The immune phenotype may require continued observation before its significance becomes clear.

For this reason, follow-up testing is not necessarily a sign that the first test failed. Reanalysis may become useful when gene-disease knowledge advances or when the child develops new clinical features. The decision depends on the original test, the strength of the continuing clinical suspicion, and whether the immune phenotype has changed.

Clinical safety while genetic results are pending

A genetic test may take weeks, while infection risk can change from day to day. We therefore manage the child’s immediate safety in parallel with laboratory investigation.

If SCID or another significant T-cell or combined immunodeficiency is suspected, live-attenuated vaccines should be withheld until a pediatric immunologist confirms that they are appropriate. This includes live rotavirus vaccine, MMR, varicella, and live intranasal influenza vaccine. The decision about other vaccines, household contacts, prophylaxis, blood products, infection precautions, and school or daycare attendance must be individualized to the child’s immune findings and local clinical protocols.

The care plan may also include:

• Tracking fever, respiratory symptoms, persistent diarrhea, unusual skin findings, and weight or growth changes.
• Reviewing previous antibiotic courses, hospitalizations, cultures, and infections by organism rather than counting infections alone.
• Confirming whether blood products require special handling in the context of suspected cellular immunodeficiency.
• Coordinating immunology, genetics, primary care, infectious disease, and other relevant specialists.
• Creating a clear urgent-care plan so that emergency teams understand the suspected immune disorder and the tests already completed.
• Avoiding treatment decisions based solely on an unconfirmed genetic finding.

The quality of life impact is part of the medical assessment. Repeated admissions, missed school, medication burden, food restrictions, fear of infection, and uncertainty around vaccines can affect the child and family even before a diagnosis is established. A good diagnostic pathway addresses these practical pressures while the immune cascade is being clarified.

When genetic testing is urgent

The urgency is highest when the child has signs of severe cellular immune dysfunction, profound or persistent lymphopenia, serious opportunistic infection, severe infection after a live vaccine, or a newborn screening result suggesting markedly reduced T-cell production. In these situations, waiting for a genetic result should not delay protective clinical management.

Genetic testing can support decisions about definitive therapies and family counseling, but the immediate pathway may rely on flow cytometry, functional assays, infection control, specialist consultation, and careful vaccine decisions. The sequence is coordinated, not strictly linear.

For less acute presentations, the team may have more time to repeat baseline studies, obtain parental samples, review the family history, and select between a focused panel and broader sequencing. This can improve interpretive accuracy without compromising care.

How long should families expect the process to take?

There is no single pediatric genetic testing timeline for immune disorders because the testing clock begins at different points for different children.

A practical sequence may look like this:

1. Clinical assessment and baseline testing: The clinician documents the infection pattern, growth, vaccine history, family history, complete blood count, and quantitative immunoglobulins.

2. Immune-cell characterization: Flow cytometry and additional immune studies clarify whether T-cell, B-cell, natural-killer-cell, or combined abnormalities are present.

3. Test selection and sample collection: The team chooses a targeted panel, singleton exome, Trio-WES, or another strategy based on the phenotype and available family samples.

4. Laboratory analysis: The sample undergoes sequencing, quality review, and variant filtering. A targeted commercial panel may have a standard turnaround of approximately four weeks, although this does not represent every laboratory or every complex case.

5. Variant interpretation: The laboratory and clinical team assess disease association, inheritance, phenotype fit, and the need for confirmatory or parental studies.

6. Clinical discussion: Results are translated into a management pathway, which may include surveillance, treatment, family testing, genetic counseling, or further immune evaluation.

7. Longitudinal review: The diagnosis is revisited as the child’s clinical presentation develops and scientific knowledge changes.

Rapid testing may be considered in critically ill children, but exact turnaround times for rapid bedside whole-genome or exome sequencing vary across medical centers and are not universal. We should be cautious about presenting a rapid result as automatically definitive; speed does not remove the need for clinical confirmation.

The longer-term outlook after testing

A molecular diagnosis can bring clarity, but its value is measured by what it changes for the child. It may establish a more precise prognosis, identify infection-prevention strategies, guide immune replacement or other therapy, determine eligibility for cellular or gene-based treatment pathways, and clarify which relatives may benefit from testing.

For some children, the outcome is not a single definitive gene result but a progressively refined diagnosis. Continued immunological monitoring may reveal whether an abnormality is persistent, whether vaccine responses improve, or whether new features support a different genetic explanation. This is especially relevant for partial or atypical phenotypes, where the early clinical presentation may not resemble a textbook disorder.

The prognosis therefore depends on the underlying condition, the severity of immune dysfunction, the timing of recognition, available treatment, infection history, and the child’s response to management. Newborn screening has particular value in severe disorders because it can create a period for protective care before the first major infection. For older children, early specialist assessment and a coordinated diagnostic pathway can still reduce preventable complications and improve quality of life.

The most reassuring message is not that genetic testing always delivers an immediate answer. It is that the pathway has several useful stages, and each stage can guide care. Baseline immunology tells us how the immune system is behaving. Flow cytometry identifies which cellular compartments require closer attention. Sequencing may reveal the molecular cause, while family studies and clinical follow-up determine what that cause means in practice.

When we approach pediatric genetic testing for immunodeficiency in this connected way, the timeline becomes easier to understand: screening identifies risk, immunological assays define the phenotype, genetic testing investigates mechanism, and long-term clinical care turns the result into a safer and more informed future for the child.